Cargando…

Eculizumab in the Treatment of Aquaporin-4 Seronegative Neuromyelitis Optica Spectrum Disorder: A Case Report

Objective: To report the case of a 35-year-old woman with treatment-resistant aquaporin-4 (AQP-4) immunoglobulin G (IgG) seronegative neuromyelitis optica spectrum disorder (NMOSD) successfully treated with eculizumab (a terminal complement inhibitor). Methods: The investigational procedures and tre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Digala, Lakshmi, Katyal, Nakul, Narula, Naureen, Govindarajan, Raghav
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8134535/ https://www.ncbi.nlm.nih.gov/pubmed/34025563 http://dx.doi.org/10.3389/fneur.2021.660741

Ejemplares similares

Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Neuromyelitis Optica Spectrum Disorder
por: Singh, Pratap, et al.
Publicado: (2021)

Clinical Experience with Eculizumab in Treatment-Refractory Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis
por: Katyal, Nakul, et al.
Publicado: (2021)

Eculizumab for acute relapse of neuromyelitis optica spectrum disorder: Case report
por: Chatterton, Sophie, et al.
Publicado: (2022)

Neuromuscular Complications With SARS-COV-2 Infection: A Review
por: Katyal, Nakul, et al.
Publicado: (2020)

Disease and Patient Characteristics Contributing to Diagnostic Delays in Patients With Guillain-Barré Syndrome
por: Pathikonda, Chakrapani, et al.
Publicado: (2021)

Eculizumab in the treatment of neuromyelitis optica spectrum disorder
por: Nabizadeh, Fardin, et al.
Publicado: (2023)

Diffuse Gonococcal Infection (DGI) in a Patient with Treatment-Refractory Acetylcholine Receptor Antibody-Positive (AChR+) Generalized Myasthenia Gravis (gMG) Treated with Eculizumab
por: Katyal, Nakul, et al.
Publicado: (2021)

Neuromyelitis Optica Spectrum Disorder
por: Cazzaniga, Juliana, et al.
Publicado: (2023)

The Detection of Retina Microvascular Density in Subclinical Aquaporin-4 Antibody Seropositive Neuromyelitis Optica Spectrum Disorders
por: Chen, Yihong, et al.
Publicado: (2020)

Deep learning-based relapse prediction of neuromyelitis optica spectrum disorder with anti-aquaporin-4 antibody
por: Wang, Liang, et al.
Publicado: (2022)

Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder
por: Frampton, James E.
Publicado: (2020)

Corrigendum: The Detection of Retina Microvascular Density in Subclinical Aquaporin-4 Antibody Seropositive Neuromyelitis Optica Spectrum Disorders
por: Chen, Yihong, et al.
Publicado: (2020)

Anti-aquaporin 4 IgG Is Not Associated With Any Clinical Disease Characteristics in Neuromyelitis Optica Spectrum Disorder
por: Schmetzer, Oliver, et al.
Publicado: (2021)

COVID-19 in a patient treated with eculizumab for aquaporin-4 neuromyelitis optica
por: Cabal-Herrera, Ana Maria, et al.
Publicado: (2021)

Correction to: Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder
por: Frampton, James E.
Publicado: (2020)

Analysis of Predictive Risk Factors in Aquaporin-4-IgG Positive Highly Active Neuromyelitis Optica Spectrum Disorders
por: Li, Yanfei, et al.
Publicado: (2021)

Editorial: Advances in neuromyelitis optica spectrum disorders
por: Cai, Yu, et al.
Publicado: (2022)

Ovarian Reserve in Women With Neuromyelitis Optica Spectrum Disorder
por: Thöne, Jan, et al.
Publicado: (2018)

Radiologically isolated aquaporin-4 antibody neuromyelitis optica spectrum disorder
por: Abdel-Mannan, Omar, et al.
Publicado: (2022)

Early Treatment Initiation With Oral Prednisolone for Relapse Prevention Alleviates Depression and Fatigue in Aquaporin-4–Positive Neuromyelitis optica Spectrum Disorder
por: Akaishi, Tetsuya, et al.
Publicado: (2021)

Serum Aquaporin 4-Immunoglobulin G Titer and Neuromyelitis Optica Spectrum Disorder Activity and Severity: A Systematic Review and Meta-Analysis
por: Liu, Jia, et al.
Publicado: (2021)

Short segment myelitis as the initial and only manifestation of aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorders
por: Fang*, Wei, et al.
Publicado: (2020)

Cortical Thinning and Ventricle Enlargement in Neuromyelitis Optica Spectrum Disorders
por: Tian, De-Cai, et al.
Publicado: (2020)

Fatal anti-aquaporin-4 seropositive neuromyelitis optica spectrum disorder in tuberculosis
por: Sridhar, Siddharth, et al.
Publicado: (2014)

Pathology of myelin oligodendrocyte glycoprotein antibody-associated disease: a comparison with multiple sclerosis and aquaporin 4 antibody-positive neuromyelitis optica spectrum disorders
por: Takai, Yoshiki, et al.
Publicado: (2023)

Neuromyelitis optica pathogenesis and aquaporin 4
por: Graber, David J, et al.
Publicado: (2008)

Seronegative Neuromyelitis Optica Spectrum Disorder following Exposure to Hepatitis B Vaccination
por: Heekin, Richard, et al.
Publicado: (2015)

Seronegative Neuromyelitis Optica Spectrum Disorder: An Unusual Presentation of Acute Brainstem Syndrome
por: Alshurafa, Zahra Haider, et al.
Publicado: (2020)

Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide
por: Hor, Jyh Yung, et al.
Publicado: (2020)

Evaluation of Thiol Homeostasis in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders
por: Arslan, Burak, et al.
Publicado: (2021)

Case Report: Interferon-Alpha-Induced Neuromyelitis Optica Spectrum Disorder
por: Rao, Jie, et al.
Publicado: (2022)

CH50 as a putative biomarker of eculizumab treatment in neuromyelitis optica spectrum disorder
por: Namatame, Chihiro, et al.
Publicado: (2021)

Anti-Aquaporin-1 Autoantibodies in Patients with Neuromyelitis Optica Spectrum Disorders
por: Tzartos, John S., et al.
Publicado: (2013)

Convergence spasm due to aquaporin-positive neuromyelitis optica spectrum disorder
por: Özçelik, Pınar, et al.
Publicado: (2017)

Transient Pulmonary Interstitial Lesions in Aquaporin-4-positive Neuromyelitis Optica Spectrum Disorder
por: Asato, Yuko, et al.
Publicado: (2018)

Different Phenotypes at Onset in Neuromyelitis Optica Spectrum Disorder Patients with Aquaporin-4 Autoimmunity
por: Long, Youming, et al.
Publicado: (2017)

Discontinuation of Immunosuppressive Therapy in Patients With Neuromyelitis Optica Spectrum Disorder With Aquaporin-4 Antibodies
por: Kim, Su-Hyun, et al.
Publicado: (2021)

Neuromyelitis Optica Spectrum Disorder With Anti-Aquaporin-4 Antibody: Outcome Prediction Models
por: Wang, Liang, et al.
Publicado: (2022)

Molecular Level Characterization of Circulating Aquaporin-4 Antibodies in Neuromyelitis Optica Spectrum Disorder
por: Li, Jie, et al.
Publicado: (2021)

Mirror-Image Lesions in Sequential Relapses of AQP4-Positive Neuromyelitis Optica Spectrum Disorder
por: Muir, Ryan T., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9jk3orr80ubd27gg2gd6ol3hjv